José Luis Zamorano

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

Željko Reiner, Alberico L. Catapano, Guy De Backer et al. · European Heart Journal · 2011 · 3.5K citations · Full text

Medicine, Cardiology, Internal Medicine +17

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

Alberico L. Catapano, Ian Graham, Guy De Backer et al. · European Heart Journal · 2016 · 3.2K citations · Full text

Medicine, Internal Medicine, Epidemiology +11

Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study

Ángel Lanas, Jesús Tornero, José Luis Zamorano · Annals of the Rheumatic Diseases · 2010 · 112 citations

Medicine, Clinical Sciences, Pharmacotherapy +17

Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia

Roberto Ferrari, Carlos Aguíar, Eduardo Alegría et al. · European Heart Journal Supplements · 2016 · 101 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Lipid‐lowering efficacy and safety of alirocumab in patients with or without diabetes: <scp>A</scp> sub‐analysis of <scp>ODYSSEY COMBO II</scp>

Lawrence A. Leiter, José Luis Zamorano, Maja Bujas‐Bobanovic et al. · Diabetes Obesity and Metabolism · 2017 · 50 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17